A Varicella-Susceptible Patient and a Biologic That Cannot Wait
A varicella-susceptible patient with steroid-refractory Crohn's disease needs an urgent biologic his disease cannot wait for, in a window too short for the vaccine that would normally come first.
Jamal B., a 24-year-old man, was six weeks into the data-collection phase of his master's thesis on urban transit planning when the bloody diarrhea and abdominal pain that had been building for two months finally became impossible to keep working through, and he has spent the past nine days in the hospital instead of the archive he'd planned to be in. His new diagnosis of severe Crohn's disease has not responded adequately to high-dose intravenous corticosteroids, and his gastroenterology team is recommending urgent escalation to infliximab. Routine pre-biologic screening turned up one complication nobody had anticipated: he has no history of chickenpox, no childhood vaccination record for varicella, and negative serology — he has simply never been exposed. He also has a nine-month-old niece he sees most weekends and adores, a detail that matters more than it would for most adults his age, since young children are among the more common sources of primary varicella exposure.
The IDSA's guideline for vaccinating the immunocompromised host — Rubin and colleagues — calls for live vaccines like varicella to be given at least four weeks before starting a TNF inhibitor, both to allow an adequate immune response to develop and to avoid the theoretical risk of disseminated vaccine-strain infection in an already-immunosuppressed host. His steroid-refractory disease course argues against tolerating that full interval; four more weeks of inadequately controlled Crohn's, in a patient already hospitalized and losing weight, carries its own real risk. What's actually achievable, though, may not be a binary choice between the full four-week delay and none at all — a partial delay of several days to a week, bridged by continued steroids or exclusive enteral nutrition, is at least logistically possible, though a week is well short of the interval considered adequate for reliable seroconversion. That is the uncomfortable shape of this decision: the delay he could actually afford is almost certainly too short to protect him, and the delay that would protect him is one his colon cannot survive.
A four-week rule against a gut that can't wait four weeks
Infliximab needs to start now, not in a week and certainly not in four. He's steroid-refractory, he's lost eight percent of his body weight in two months, and every additional week of inadequately controlled Crohn's raises his risk of a complication — stricture, perforation, the kind of outcome that changes his surgical future — that dwarfs the varicella question in front of us tonight.
I'm not proposing the full four weeks — I don't think his disease tolerates that either.
But I don't think 'now' and 'four weeks from now' are the only two options worth naming out loud before we default to the fastest one. A bridge of several more days on his current steroids, or adding exclusive enteral nutrition to buy a short window, is at least logistically possible and would get him some real interval before the first infliximab dose — the question is whether a partial delay that short is long enough to matter immunologically, and honestly, I don't have confident data telling me it is.
That uncertainty is the actual answer, I think, not something to resolve further tonight. If a week doesn't reliably produce protective seroconversion anyway, delaying infliximab that long costs him real disease-control time for an uncertain immunologic benefit — that's a worse trade than either of the two positions already on the table, not a genuine middle ground.
I'd start infliximab now and build the actual safety net around his ongoing susceptibility instead: postexposure prophylaxis on file for the day he's exposed, whether that's varicella-zoster immune globulin or high-dose valacyclovir depending on timing and what's available — plus explicit instructions to call the moment his niece or anyone else around him breaks out in a rash, rather than waiting to see if he feels sick first.
One thing I want written on that standing order in words: ten days, not ninety-six hours. The four-day figure is the superseded one, and it is still quoted often enough that a patient recognized on day five gets turned away from a drug he is in fact still eligible for.
Agreed: infliximab started this week without a vaccine-delay bridge, given the pharmacist's point that a partial delay likely traded real disease-control time for uncertain immunologic benefit. A written postexposure-prophylaxis plan was placed in his chart — varicella-zoster immune globulin as soon as possible after a recognized exposure and within 10 days rather than the 96 hours often quoted, high-dose valacyclovir if that window has passed — along with explicit instructions for his family, including for the niece he sees weekly, to flag any exposure immediately rather than waiting for symptoms.
Not addressed, and worth naming as a real gap rather than an oversight: nobody circled back to whether he should be revaccinated against varicella at all once infliximab is eventually stopped, if it ever is. The visit ended focused entirely on managing the risk now open, not on when or whether it might someday close.